With the generous support of PotashCorp, LMHS purchased its first Tru-D SmartUVC robot in August and has been using the technology daily to disinfect patient areas before surgery at the hospital, as well as in the hospital’s isolation rooms, as a part of the terminal cleaning process. Community members rallied together at a recent fundraising event, sponsored by the Lima Memorial Foundation, to fund a second disinfecting robot.
The health care leaders at LMHS aren’t the only ones to recognize Tru-D’s effectiveness as of late. In October, research leaders in UVC disinfection released the results of the first randomized clinical trial on UVC disinfection, in which Tru-D SmartUVC was the only device used. Overall, results of the landmark Benefits of Enhanced Terminal Room Disinfection study, which was funded by the Centers for Disease Control and Prevention, showed that enhanced terminal room disinfection strategies decreased the cumulative incidence of multidrug-resistant organisms by 10 to 30 percent, and the largest decreases were seen when Tru-D was added to the standard cleaning strategy, (Daniel J. Sexton, MD, et al., 2015). It also showed that the process of incorporating Tru-D into hospital disinfection protocols for highest risk rooms was seamless, and adding a cycle of UVC dosing only added up to 10 minutes to the total room turnover.
Tru-D SmartUVC is the only UV disinfection device backed by a CDC-funded randomized clinical trial to show that it is capable of reducing the transmission of health care-associated infections by up to 30 percent. Hundreds of Tru-Ds have been deployed to disinfect hospitals across the globe, fighting deadly pathogens such as MRSA, CRE, C. diff, VRE, MERS, Ebola and many more. An effective and innovative technology backed by sound science, Tru-D SmartUVC is on a mission to eradicate HAIs making hospitals a safer place for patients and staff.